NCT01363063 - Study of the Tolerability of Ketorolac Tromethamine Following Intranasal Administration in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

June 30, 2007

Conditions

Healthy Volunteers

Interventions

DRUG

Ketorolac tromethamine

One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril

DRUG

Ketorolac tromethamine

One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril

Trial Locations (1)

Unknown

ICON Developmental Solutions, Manchester